The mRNA cancer vaccine biologic lines market is projected to grow at a CAGR of 11.87% from 2026 to 2035, rising from USD 613.17 Million in 2026 to an estimated USD 1,732.09 Million by 2035 (2025 base USD 564.2 Million). Growth is driven by commercialization of customized mRNA-based oncology therapies, higher investment in advanced biologics production, and mRNA platforms moving to commercial-scale manufacturing and late-stage trials. Major players such as BioNTech and Moderna add to market revenue.
Market Snapshot
- Revenue, 2026: 613.17 Million
- Forecast, 2035: 1,732.09 Million
- CAGR, 2026-2035: 11.87%
- Report Coverage: Global
Key Companies
- Moderna Inc.
- BioNTech SE
- CureVac AG
- Translate Bio Inc.
- Arcturus Therapeutics Holdings Inc.
- Gritstone Oncology Inc.
- Others
About Healthcare Foresights
Healthcare Foresights provides market research and consulting across the healthcare and life sciences industry, combining industry research, analytical expertise and technology-enabled solutions to help companies, investors and decision-makers identify opportunities and drive growth. For the full report, customization or a sample, contact our team.